Phase Two
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma (NCT03936452) | Sun Yat-sen University | 2019-04-28 |
Track Phase Two automatically
Every clearance here is in the API, with alerts when new ones post.